These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24842414)

  • 1. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.
    Wong FL; Bhatia S; Landier W; Francisco L; Leisenring W; Hudson MM; Armstrong GT; Mertens A; Stovall M; Robison LL; Lyman GH; Lipshultz SE; Armenian SH
    Ann Intern Med; 2014 May; 160(10):672-83. PubMed ID: 24842414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.
    Yeh JM; Nohria A; Diller L
    Ann Intern Med; 2014 May; 160(10):661-71. PubMed ID: 24842413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer.
    Ehrhardt MJ; Ward ZJ; Liu Q; Chaudhry A; Nohria A; Border W; Fulbright JM; Mulrooney DA; Oeffinger KC; Nathan PC; Leisenring WM; Constine LS; Gibson TM; Chow EJ; Howell RM; Robison LL; Armstrong GT; Hudson MM; Diller L; Yasui Y; Armenian SH; Yeh JM
    J Clin Oncol; 2020 Nov; 38(33):3851-3862. PubMed ID: 32795226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors.
    Steingart RM; Liu JE; Oeffinger KC
    Ann Intern Med; 2014 May; 160(10):731-2. PubMed ID: 24842420
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
    Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
    Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
    JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
    Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
    Gandjour A; Ostwald DA
    Pharmacoeconomics; 2018 Oct; 36(10):1285-1296. PubMed ID: 30054868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health and economic benefits of increased beta-blocker use following myocardial infarction.
    Phillips KA; Shlipak MG; Coxson P; Heidenreich PA; Hunink MG; Goldman PA; Williams LW; Weinstein MC; Goldman L
    JAMA; 2000 Dec; 284(21):2748-54. PubMed ID: 11105180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.
    Abosoudah I; Greenberg ML; Ness KK; Benson L; Nathan PC
    Pediatr Blood Cancer; 2011 Sep; 57(3):467-72. PubMed ID: 21280201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
    Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
    Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
    Lipshultz SE; Lipsitz SR; Sallan SE; Simbre VC; Shaikh SL; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2002 Dec; 20(23):4517-22. PubMed ID: 12454107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.
    Shekelle P; Morton S; Atkinson S; Suttorp M; Tu W; Heidenreich P; Gubens M; Maglione M; Jungvig L; Roth E; Newberry S
    Evid Rep Technol Assess (Summ); 2003 Jul; (82):1-6. PubMed ID: 14571595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.